======= TADA2A =======
== Gene Information ==
* **Official Symbol**: TADA2A
* **Official Name**: transcriptional adaptor 2A
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=6871|6871]]
* **UniProt**: [[https://www.uniprot.org/uniprot/O75478|O75478]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=TADA2A&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TADA2A|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/602276|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. Required for the function of some acidic activation domains, which activate transcription from a distant site (By similarity). Binds double- stranded DNA. Binds dinucleosomes, probably at the linker region between neighboring nucleosomes. Plays a role in chromatin remodeling. May promote TP53/p53 'Lys-321' acetylation, leading to reduced TP53 stability and transcriptional activity (PubMed:22644376). May also promote XRCC6 acetylation thus facilitating cell apoptosis in response to DNA damage (PubMed:22644376). {ECO:0000250|UniProtKB:Q8CHV6, ECO:0000269|PubMed:19103755, ECO:0000269|PubMed:22644376}.
|Myb DNA-binding|
|SWIRM|
|PCAF complex|
|SAGA-type complex|
|positive regulation of histone acetylation|
|positive regulation of peptidyl-lysine acetylation|
|positive regulation of protein acetylation|
|histone H3 acetylation|
|histone acetyltransferase activity|
|regulation of histone acetylation|
|regulation of peptidyl-lysine acetylation|
|regulation of protein acetylation|
|positive regulation of histone modification|
|positive regulation of chromatin organization|
|histone acetylation|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|chromosome|
|protein acetylation|
|regulation of histone modification|
|chromatin remodeling|
|positive regulation of chromosome organization|
|protein acylation|
|regulation of chromatin organization|
|transcription coactivator activity|
|peptidyl-lysine modification|
|regulation of chromosome organization|
|histone modification|
|covalent chromatin modification|
|chromatin binding|
|positive regulation of organelle organization|
|chromatin organization|
|peptidyl-amino acid modification|
|chromosome organization|
|positive regulation of cellular component organization|
|positive regulation of protein modification process|
|regulation of organelle organization|
|DNA binding|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of cellular protein metabolic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|positive regulation of protein metabolic process|
|positive regulation of RNA metabolic process|
|regulation of protein modification process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp240|Pyridostatin 4μM R05 exp240]]|1.71|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|1.71|
|[[:results:exp8|Brefeldin A 0.02μM R00 exp8]]|1.74|
|[[:results:exp448|Ammonium tetrathiomolybdate 10μM R08 exp448]]|1.76|
|[[:results:exp343|Centrinone 0.5μM R07 exp343]]|1.8|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|1.89|
|[[:results:exp360|Genistein 15μM R07 exp360]]|1.92|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|1.95|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|2.05|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.07|
|[[:results:exp209|Deguelin 0.15μM R05 exp209]]|2.17|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|2.28|
|[[:results:exp211|AICAR 240μM R05 exp211]]|2.33|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|2.43|
|[[:results:exp248|UM0131023 0.05μM R05 exp248]]|2.51|
|[[:results:exp135|MS023 7μM R03 exp135]]|3.16|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|3.47|
|[[:results:exp134|MS023 2μM R03 exp134]]|3.53|
|[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|3.65|
^Gene^Correlation^
|[[:human genes:z:zzz3|ZZZ3]]|0.66|
|[[:human genes:y:yeats2|YEATS2]]|0.542|
|[[:human genes:h:heatr3|HEATR3]]|0.468|
|[[:human genes:f:faf2|FAF2]]|0.463|
|[[:human genes:m:mbip|MBIP]]|0.46|
|[[:human genes:u:ubqln1|UBQLN1]]|0.424|
|[[:human genes:c:csrp2bp|CSRP2BP]]|0.413|
|[[:human genes:m:mysm1|MYSM1]]|0.407|
|[[:human genes:w:wdr5|WDR5]]|0.407|
Global Fraction of Cell Lines Where Essential: 13/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|1/28|
|bone|1/25|
|breast|0/33|
|central nervous system|2/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|1/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|1/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3334
* **Expression level (log2 read counts)**: 5.58
{{:chemogenomics:nalm6 dist.png?nolink |}}